吉利德科学 2025年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No.0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) GILEAD SCIENCES, INC.INDEX PARTI.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial StatementsCondensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive Income (Loss)Condensed Consolidated Statements of Stockholders’ Equity Condensed Consolidated Statements of Cash Flows Notes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations PARTII.OTHER INFORMATION Item 1.Legal ProceedingsItem1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits SIGNATURES This Quarterly Report on Form 10-Q, including Part I, Item 2. Management’s Discussion and Analysis of Financial Conditionand Results of Operations and Part II, Item1A. Risk Factors, contains forward-looking statements regarding future events and ourfuture results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities ExchangeAct of 1934, as amended. Words such as “ambition,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,”“goal,” “hope,” “intend,” “may,” “might,” “outlook,” “plan,” “priority,” “project,” “seek,” “should,” “target” and variations ofsuch words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other thanstatements of historical fact are forward-looking statements, including statements regarding overall trends; operating cost, productsales and revenue trends; liquidity and capital needs; plans and expectations with respect to products, product candidates, corporate We have based these forward-looking statements on our current expectations about future events. These statements are notguarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results oroutcomes may differ materially from those suggested by these forward-looking statements for various reasons, including thoseidentified in Part II, Item1A. Risk Factors of this Quarterly Report on Form 10-Q. Given these risks and uncertainties, you arecautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are madeonly as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of GILEAD SCIENCES,INC.CONDENSED CONSOLIDATED BALANCE SHEETS GILEAD SCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1.SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated FinancialStatements of Gilead Sciences, Inc. (“Gilead,” “we,” “our” or “us”) should be read in conjunction with the audited ConsolidatedFinancial Statements and the related notes thereto for the year ended December31, 2024, included in our Annual Report on Form 10- These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles forinterim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sumor recalculate due to rounding. Disaggregation of Revenues Contract Balances The following table summarizes our contract balances: 3.FAIR VALUE MEASUREMENTS Recurring Fair Value Measurements The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within thefair value hierarchy: Level 2 Inputs Foreign Currency Derivative Contracts Our foreign currency derivative contracts have maturities of18months or less and all are with counterparties that have aminimum credit rating of A- or equivalent by S&P Global Ratings, Moody’s Investors Service, Inc. or Fitch Ratings, Inc. We estimatethe fair values of these contracts by utilizing an income-based industry standard valuation model for which all significant inputs areobservable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate Level 3 Inputs Contingent Consideration Liability In connection with our first quarter 2021 acquisition of MYR GmbH, we are subject to a potential contingent considerationpayment of up to €300million, subject to customary adjustments, which is revalued each reporting period using probability-weighted